These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36908118)

  • 1. Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN).
    Muramatsu T; Masuda S; Kotoku N; Kozuma K; Kawashima H; Ishibashi Y; Nakazawa G; Takahashi K; Okamura T; Miyazaki Y; Tateishi H; Nakamura M; Kogame N; Asano T; Nakatani S; Morino Y; Katagiri Y; Ninomiya K; Kageyama S; Takahashi H; Garg S; Tu S; Tanabe K; Ozaki Y; Serruys PW; Onuma Y
    Circ J; 2023 May; 87(6):857-865. PubMed ID: 36908118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study.
    Kogame N; Guimarães PO; Modolo R; De Martino F; Tinoco J; Ribeiro EE; Kawashima H; Ono M; Hara H; Wang R; Cavalcante R; Moulin B; Falcão BAA; Leite RS; de Almeida Sampaio FB; Morais GR; Meireles GC; Campos CM; Onuma Y; Serruys PW; Lemos PA
    JACC Cardiovasc Interv; 2020 Oct; 13(19):2251-2262. PubMed ID: 32950419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.
    Lee JM; Jung JH; Park KW; Shin ES; Oh SK; Bae JW; Rhew JY; Lee N; Kim DB; Kim U; Han JK; Lee SE; Yang HM; Kang HJ; Koo BK; Kim S; Cho YK; Shin WY; Lim YH; Rha SW; Kim SY; Lee SY; Kim YD; Chae IH; Cha KS; Kim HS
    Trials; 2015 Sep; 16():409. PubMed ID: 26374625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention.
    Yamamoto K; Natsuaki M; Watanabe H; Morimoto T; Obayashi Y; Nishikawa R; Ando K; Suwa S; Isawa T; Takenaka H; Ishikawa T; Tamura T; Kawahatsu K; Hayashi F; Akao M; Serikawa T; Mori H; Kawamura T; Hagikura A; Shibata N; Ono K; Kimura T;
    JACC Cardiovasc Interv; 2024 May; 17(9):1119-1130. PubMed ID: 38749592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel Monotherapy After Percutaneous Coronary Intervention for Chronic Coronary Syndrome: Insights From ASET Pilot Studies.
    Masuda S; Tanabe K; Guimarães PO; Muramatsu T; Ozaki Y; De Martino F; Kozuma K; Garg S; Kotoku N; Ninomiya K; Kageyama S; Lemos PA; Onuma Y; Serruys PW
    JACC Asia; 2024 Mar; 4(3):171-182. PubMed ID: 38463674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
    Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study.
    Masuda S; Muramatsu T; Ishibashi Y; Kozuma K; Tanabe K; Nakatani S; Kogame N; Nakamura M; Asano T; Okamura T; Miyazaki Y; Tateishi H; Ozaki Y; Nakazawa G; Morino Y; Katagiri Y; Garg S; Hara H; Ono M; Kawashima H; Lemos PA; Serruys PW; Onuma Y
    AsiaIntervention; 2023 Mar; 9(1):39-48. PubMed ID: 36936091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry.
    Ishida M; Takahashi F; Goto I; Niiyama M; Saitoh H; Sakamoto T; Maegawa Y; Osaki T; Nishiyama O; Endo H; Sakamoto R; Kojima T; Koeda Y; Kimura T; Itoh T; Morino Y;
    Cardiovasc Interv Ther; 2020 Oct; 35(4):398-404. PubMed ID: 32776221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
    Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
    JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-Month Dual Antiplatelet Therapy Followed by P2Y
    Ishida M; Shimada R; Takahashi F; Niiyama M; Ishisone T; Matsumoto Y; Taguchi Y; Osaki T; Nishiyama O; Endo H; Sakamoto R; Tanaka K; Koeda Y; Kimura T; Goto I; Ninomiya R; Sasaki W; Itoh T; Morino Y;
    Circ J; 2024 May; 88(6):876-884. PubMed ID: 38569870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.
    Yamamoto K; Watanabe H; Morimoto T; Obayashi Y; Natsuaki M; Yamaji K; Domei T; Ogita M; Ohya M; Tatsushima S; Suzuki H; Tada T; Ishii M; Nikaido A; Watanabe N; Fujii S; Mori H; Nishikura T; Suematsu N; Hayashi F; Komiyama K; Shigematsu T; Isawa T; Suwa S; Ando K; Kimura T;
    JACC Cardiovasc Interv; 2023 Jan; 16(1):19-31. PubMed ID: 36599584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
    van Geuns RJ; Chun-Chin C; McEntegart MB; Merkulov E; Kretov E; Lesiak M; O'Kane P; Hanratty CG; Bressollette E; Silvestri M; Wlodarczak A; Barragan P; Anderson R; Protopopov A; Peace A; Menown I; Rocchiccioli P; Onuma Y; Oldroyd KG
    EuroIntervention; 2022 Apr; 17(18):1467-1476. PubMed ID: 35285803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy With Prasugrel After Dual-Antiplatelet Therapy for Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk　- A Prospective Cohort Study (PENDULUM mono Study).
    Nakamura M; Morino Y; Kakuta T; Hata Y; Takamisawa I; Tanabe K; Anzai H; Takahashi A; Kadota K; Suzuki H; Wakatsuki T; Okayama H; Yamashita J; Akasaka T; Yokoi H; Nakagami T; Higuchi Y; Yamaguchi J; Kimura T; Harada A; Kuroda T; Takita A; Iijima R; Murakami Y; Saito S
    Circ J; 2020 Dec; 85(1):27-36. PubMed ID: 33162490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.
    Mehran R; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Wang J; Valgimigli M;
    JACC Cardiovasc Interv; 2021 Sep; 14(17):1870-1883. PubMed ID: 34503737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents.
    Toba T; Shinke T; Otake H; Sugizaki Y; Takeshige R; Onishi H; Nagasawa A; Tsukiyama Y; Yanaka K; Nagano Y; Yamamoto H; Kawamori H; Matsuura A; Ishihara T; Matsumoto D; Igarashi N; Hayashi T; Yasaka Y; Kadotani M; Fujii T; Shite J; Okada M; Sakakibara T; Hirata KI
    Heart Vessels; 2019 Jun; 34(6):936-947. PubMed ID: 30599059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients.
    Pivato CA; Reimers B; Testa L; Pacchioni A; Briguori C; Musto C; Esposito G; Piccolo R; Lucisano L; De Luca L; Conrotto F; De Marco A; Franzone A; Presbitero P; Ferrante G; Condorelli G; Paradies V; Sardella G; Indolfi C; Condorelli G; Stefanini GG
    J Am Heart Assoc; 2022 Mar; 11(6):e023454. PubMed ID: 35114814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.
    Natsuaki M; Watanabe H; Morimoto T; Yamamoto K; Obayashi Y; Nishikawa R; Ando K; Domei T; Suwa S; Ogita M; Isawa T; Takenaka H; Yamamoto T; Ishikawa T; Hisauchi I; Wakabayashi K; Onishi Y; Hibi K; Kawai K; Yoshida R; Suzuki H; Nakazawa G; Kusuyama T; Morishima I; Ono K; Kimura T
    Circulation; 2024 Feb; 149(8):585-600. PubMed ID: 37994553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study.
    van der Sangen NMR; Claessen BEPM; Küçük IT; den Hartog AW; Baan J; Beijk MAM; Delewi R; van de Hoef TP; Knaapen P; Lemkes JS; Marques KM; Nap A; Verouden NJW; Vis MM; de Winter RJ; Kikkert WJ; Appelman Y; Henriques JPS
    EuroIntervention; 2023 May; 19(1):63-72. PubMed ID: 36734020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
    Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.